본문 바로가기

카테고리 없음

Musculoskeletal Pain Market Share Analysis By DelveInsight

Musculoskeletal Pain Market Share

Musculoskeletal pain affects the bones, muscles, ligaments, tendons, and nerves, with the pain ranging from mild to severe enough to interfere with day-to-day life. It may start suddenly and be short-lived, which is called acute pain. Pain that lasts for more time is called chronic pain. Musculoskeletal pain can be localized in one area, or widespread.

  • According to the World Health Organization, while the prevalence of musculoskeletal conditions varies by age and diagnosis, between 20-33% of people across the globe live with a painful musculoskeletal condition.
  • The total prevalent population of Musculoskeletal Pain in the 7 major markets ranges from approximately 252,376,708 cases in 2017.
  • Among the EU5 countries, UK had the highest prevalent population of Musculoskeletal Pain, followed by Italy and Spain. On the other hand, France had the lowest prevalent population.
  • In terms of gender, most of the patients diagnosed with Musculoskeletal Pain are female as compared to males in the 7MM. 

DelveInsight's "Musculoskeletal Pain Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Musculoskeletal Pain market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Musculoskeletal Pain market shares of the individual therapies, a detailed current Musculoskeletal Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.

Musculoskeletal Pain Market Share

The Musculoskeletal Pain market size shall experience a positive growth during the forecast period owing to the increasing healthcare expenditure, rise in R&D activities, awareness among patients about the treatment options.  Extensive research and development activities of pharmaceutical companies for developing the therapies for Musculoskeletal Pain and the expected launch of new therapies will also significantly impact the market growth. 

 

The Musculoskeletal Pain market analysis section of the report helps to understand the current and forecasted Musculoskeletal Pain market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Musculoskeletal Pain market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Musculoskeletal Pain Epidemiology Forecast

The Musculoskeletal Pain epidemiology section covers insights about historical and current Musculoskeletal Pain patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Musculoskeletal Pain Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.  

Musculoskeletal Pain Market Trends

The rising number of patients with Musculoskeletal Pain, increasing awareness, and increasing research and development activities are some of the factors which are expected to contribute towards the Musculoskeletal Pain market growth during the forecast period.

 

Musculoskeletal Pain Companies involved in developing therapies include Eli Lilly, Pfizer, Mesoblast, Regeneron Pharmaceuticals, Braeburn Pharmaceuticals, and many others. Musculoskeletal Pain Therapies Covered in the report include Tanezumab, Fasinumab, MPC-06-ID, CAM2038, and many more. 

 

For more details, visit: Musculoskeletal Pain Market Share